ImmunOs’ approach is based on the identification of specific human leukocyte antigen (HLA) molecules that hyper-activate the immune system of patients with severe autoimmune disorders. The company has utilized this discovery to develop an HLA-based technology platform to generate a novel class of biologic therapeutics for the treatment of cancer and autoimmune disease.
ImmunOs has established a comprehensive data set of validated results with a global team of scientific and commercial immunotherapy, immunology, and oncology experts. In preclinical studies, therapeutic efficacy of the Company’s lead program, IOS-1002, has been demonstrated as monotherapy and in combination with standard-of-care cancer therapies.
ImmunOs’ mission is to develop the next generation of novel immunotherapies that will improve the lives of patients with serious diseases.
ImmunOs’ HLA-based pipeline includes first-in-class immunotherapies for the treatment of cancer and autoimmune disease.